Keyphrases
Psoriasis
100%
Atopic Dermatitis
83%
Eczema
51%
Systemic Sclerosis
46%
Scleroderma
41%
Interleukin-17 (IL-17)
40%
Moderate-to-severe Atopic Dermatitis
39%
Dupilumab
32%
Inflammatory Skin Diseases
28%
T Cells
25%
Atopic Eczema
24%
Interleukin-22 (IL-22)
24%
Keratinocytes
23%
Moderate-to-severe Psoriasis
20%
T Helper 17 (Th17)
19%
Optoacoustic Mesoscopy
19%
Upadacitinib
19%
Immune Response
19%
Germany
18%
Allergy
18%
Severity Index
16%
Area Index
16%
Inflammation
16%
Psoriasis Pathogenesis
15%
Disease Progression
15%
Fumaric Acid Esters
14%
EUSTAR
14%
Diffuse Cutaneous Systemic Sclerosis
14%
Molecular Diagnostics
14%
Chronic mucocutaneous Candidiasis
14%
Guselkumab
14%
Itch
13%
Chronic Inflammatory Skin Disease
12%
Generalized Pustular Psoriasis
11%
Raster Scanning
11%
Skin Diseases
11%
EAACI
11%
Skin Fibrosis
11%
Comorbidity
10%
Risk Factors
10%
Systemic Treatment
10%
Epidermis
10%
Digital Ulcers
10%
Pruritus
10%
Research Cohort
10%
Dermatologist
9%
Autoantibodies
9%
Modified Rodnan Skin Score (mRSS)
9%
Atopy Patch Test
9%
Disease Duration
9%
Immunology and Microbiology
Eczema
61%
Atopic Dermatitis
60%
Systemic Scleroderma
47%
Cytokine
47%
Dermatitis
43%
Interleukin 17
41%
T Cell
37%
Keratinocyte
34%
Immunity
34%
Scleroderma
31%
Immune Response
30%
Autoantibodies
13%
Chronic Mucocutaneous Candidiasis
13%
Innate Immune System
12%
Dupilumab
12%
Skin Allergy
12%
Comorbidity
12%
Prevalence
12%
Microbiome
10%
Candida
9%
Tumor Necrosis Factor
9%
Gene Expression
9%
Synovitis
8%
Interleukin 22
8%
Transcriptomics
8%
Atopy
8%
Wound Healing
8%
Immunocompetent Cell
8%
Systemic Inflammation
7%
Dendritic Cell
7%
Biological Product
7%
Th22 Cell
7%
Th17 Cell
7%
Secretion (Process)
7%
Immunoglobulin E
7%
Toll-Like Receptor
7%
Interleukin 4
6%
B Cell
6%
Interleukin 6
6%
Patch Test
6%
Mediator
6%
Transcriptome
6%
Supernatant
6%
Allergen
6%
Immunotherapy
6%
Macrophage
6%
Neutrophil
6%
Hapten
6%
Transcription Factors
5%
Chemokine
5%
Medicine and Dentistry
Psoriasis
54%
Atopic Dermatitis
51%
Systemic Scleroderma
44%
Diseases
37%
Eczema
31%
Dermatology
28%
Scleroderma
25%
Dermatitis
25%
Biological Marker
20%
Systemic Therapy
16%
Diagnosis
16%
Psoriasis Vulgaris
13%
Interleukin 17
12%
Disease Exacerbation
12%
Guselkumab
11%
Infection
10%
Pruritus
10%
Immunity
10%
T Cell
10%
Personalized Medicine
9%
Molecular Diagnostics
9%
Dupilumab
9%
Hand Eczema
9%
Disease Duration
9%
Generalized Pustular Psoriasis
9%
Cytokine
8%
Biological Product
8%
Fumaric Acid
8%
Skin Fibrosis
8%
Disease Course
7%
Keratinocyte
7%
Finger Ulcer
7%
Synovitis
7%
Inflammatory Disorder
6%
Severe Acute Respiratory Syndrome Coronavirus 2
6%
Treatment Response
6%
Disease Severity
6%
Clinical Trial
6%
Prospective Study
5%
Targeted Therapy
5%
Adolescence
5%
Prevalence
5%
Lung
5%
Autoantibodies
5%
COVID-19
5%
Chronic Urticaria
5%
Mucocutaneous Candidiasis
5%
Apremilast
5%
Lebrikizumab
5%
Upadacitinib
5%
